Archives: Speakers

Emma has spent the last four years working to advance sustainable food systems. She is currently working at Huel, helping to deliver their mission of improving the health of people and the planet through complete and convenient nutrition. 

David recently joined GlobalData’s medical devices consulting practice after 3 years providing guidance to some of the industry’s largest companies, working in a variety of segments including surgery, patient monitoring, oncology, neurology, orthopedics, artificial intelligence, augmented reality, care communications, and wound care.

With 25 years of experience in the medical device industry, David has held roles in Corporate Strategy, Mergers & Acquisitions, and finally as Director of Innovation, where he led a advanced technology initiatives for a global medical device company.

Among David’s areas of expertise is a unique combination of experience in innovation and intellectual property. As an attorney, David’s practice emphasized intellectual property, including patent law, and in his role as Director of Innovation for a large medical device company David was an inventor on over 100 patents.

David holds a JD from Willamette University of Law and a certificate in healthcare economics from the University of Washington.

Ruthie Davi is a Statistician and senior Vice President, Data Science at Medidata (a Dassault Systemes Company) and has a background in pharmaceutical clinical trials with more than 20 years working as a Statistical Reviewer, Team Leader, and Deputy Division Director in the Office of Biostatistics in CDER at FDA. At Medidata,  Ruthie is part of a team creating analytical tools to improve the efficiency and rigor of clinical trials, an example of which is the Synthetic Control work. Ruthie holds a Ph.D. in Biostatistics from George Washington University.

John is a results-driven leader with a genuine passion for turning business strategies into reality through financial planning and analysis across various industries. He has a knack for financial modeling, budgeting, strategic planning, and variance analysis, which helps me tackle complex challenges and support data-driven decision-making.

Throughout his career, he’s crafted and executed innovative financial strategies, streamlined processes, and led cost-saving initiatives that have significantly boosted operational efficiency and performance. He’s managed multi-million-dollar budgets and steered investment strategies for complex project portfolios, making sure resources are used wisely to meet strategic goals.

He’s also committed to building and empowering high-performing teams. He’s spearheaded organizational transformations, enhanced the scalability of financial operations, and created talent acquisition strategies and leadership programs to support diversity and inclusion.

Michelle Wetherby has 30 years’ experience in clinical trial execution and currently serves as Director of Clinical Research and Operations for Terumo Neuro. In this role she is responsible for the conduct studies for ischemic and hemorrhagic stroke. Prior to joining Terumo, she held several industry roles focused on the conduct of global medical device trials and led the development and implementation of a novel risk assessment tool and risk-based monitoring framework to support a novel monitoring approach. Ms. Wetherby is adept at assembling global teams to provide scalable central services to support critical clinical trials activities. She holds a MBA from St. Mary’s University and has presented and published on several topics.

Sarah Mische, PhD is an experienced Clinical Affairs leader with a strong background in product development, regulatory affairs, and quality systems. Her strengths include building high functioning teams and critical infrastructure at large and small medical device and biotech companies to drive clinical development programs and successful interactions with regulatory agencies. Sarah’s work on novel therapies includes implantable neuromodulation systems, bioabsorbable polymers, and infectious diseases.

Douglas joined Retail Banker International in 2005 and has edited RBI along with sister title Electronic Payments International since 2010. In addition, he has editorial responsibility for GlobalData’s wealth management title Private Banker Intl. Douglas chaired industry group The Digital Banking Club from 2013-2018 and is a regular speaker and moderator on the conference circuit.

Fatima serves as the Vice President of Global Patient Affairs at Blueprint Medicines, a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology.

In her role, Fatima leads transformative collaborations with external advocacy groups, empowering and educating those affected by systemic mastocytosis. She has led the launch of significant initiatives such as GRTY Health’s SM patient platform, MastoConnect (https://mastoconnect.com), and Colors of SM (https://www.colorsofsm.com/), in partnership with the advocacy community, and actively chairs the Equity, Diversity, and Inclusion (ED&I) patient committee, which looks to address the needs of marginalized and underrepresented communities.

With over two decades of experience in the biopharma sector, Fatima is a dedicated and passionate advocate for patients. Celebrated by PharmaVoice 100 as one of the most inspiring leaders in patient advocacy, her work focuses on amplifying patient voices and harnessing the collective power of individuals to make a positive impact. Fatima is committed to enhancing patient engagement in the development of transformative medicines, ensuring that the patient perspective is integral to every stage of the process.

She inspires her colleagues to foster a culture of purpose-driven advocacy, ensuring that patient welfare remains at the forefront of their mission. Beyond her professional role, Fatima is deeply involved in civic activities, continually dedicating herself to enhancing patient welfare and advocacy on a broader scale.